{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 25,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide presents preclinical efficacy data for NXP800 in specific genetic subtypes of endometrial cancer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/11",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "chart",
      "text": "KLE (ARID1B mutation/poorly differentiated) tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b1b2f15-e5ca-43f8-9e86-88c3e4fad3d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.67,
        "y": 0.45
      },
      "kind": "chart",
      "text": "SNG-M (ARID1a mutation) tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45d69f88-fa34-48c8-8d3f-b698ce1416d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "chart",
      "text": "RL95-2 (ARID1a/ARID1b concurrent mutation) tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58fbc103-2737-4913-9a16-61aac7aacab7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "list",
      "text": "ARID1A is the most frequently mutated SWI/SNF subunit with an estimated prevalence of 35% in endometrial carcinomas. Inactivation of ARID1B is highly prevalent in undifferentiated and dedifferentiated endometrial cancers (approx. 36%), often concurrent with ARID1a, and is associated with an aggressive phenotype. NXP800 demonstrated robust antitumor activity in ARID1A and ARID1B mutated xenografts of endometrial carcinoma, at a well-tolerated dose, including in models of poorly differentiated tumors, supporting the clinical development of NXP800 in endometrial cancer.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eef9466-ce4a-4bcc-ab96-7eb0f0c22786",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Potent Antitumor Activity in ARID1a/ARID1b Mutated Endometrial Carcinoma Xenografts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "659afcd1-f027-46eb-b134-eccb7d97a65f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "9ba638df-332a-4b15-a2bf-a27225c05ef4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document highlights the potential market opportunity for NXP800 and NXP900 in multiple cancers.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}